Publications by authors named "G Dell'Agnello"
Article Synopsis
- OVERCOME (EU) is a study focusing on migraine and severe headaches in Spain and Germany, part of a larger international research project.
- The survey gathered data from adults who experienced migraines in the past year, analyzing both overall and subcohort cases with more intense symptoms.
- Results indicated that the majority of participants experienced moderate to severe pain, many reported significant disability and reduced quality of life, and while most used acute medications, only a minority used triptans specifically.
Objectives: Randomized controlled trials (RCTs) have established the efficacy of galcanezumab, an antibody binding calcitonin gene-related peptide (CGRP) ligand, in the preventive treatment of migraine. The objective was to summarize real-world data evaluating galcanezumab in the preventive treatment of migraine, to complement RCT results with evidence observed in clinical practice.
Methods: A literature search was conducted to identify real-world studies evaluating galcanezumab in the treatment for patients with migraine.
Objectives: Given the substantial disease burden, appropriate and effective management of migraine is a public health priority. To gain insights into real-world migraine management practices in Taiwan, current treatment patterns, costs, and health care resource use were assessed.
Methods: This was a retrospective, longitudinal study using the Taiwan National Health Insurance Research Database.
Background: Insights into the burden, needs and treatment of migraine from internet-based surveys in diverse real-world migraine populations are needed, especially at a time when novel preventive migraine medications are becoming part of the therapeutic armamentarium. The objectives of this analysis are to describe traditional preventive (orals and onabotulinum toxin A) treatment patterns in the OVERCOME (EU) study migraine cohort, as well as treatment patterns and patient satisfaction with current treatment in a subgroup of respondents eligible for migraine preventive medication.
Methods: The cross-sectional non-interventional OVERCOME (EU) study was conducted (October 2020-February 2021) via an online survey among adults (aged ≥ 18 years) resident in Germany or Spain.